Search clinical trials for: Folfox plus Bevacizumab and reolysin

Total 7026 results

Canadian Cancer Trials Group
Oncolytics Biotech

Completed

Reolysin in Combination With FOLFOX6 and Bevacizumab or FOLFOX6 and Bevacizumab Alone in Metastatic Colorectal Cancer

Colorectal Cancer

Canada
Istituto Scientifico Romagnolo per lo Studio e...

Completed

Sequential Treatment Strategy for Metastatic Colorectal Cancer (ITACa)

Metastatic Colorectal Cancer

Italy
Peking University

Completed

HAIC With Oxaliplatin, 5-FU and Bevacizumab Plus Intravenous Toripalimab for Advanced BTC

Advanced Biliary Tract Cancer

China
AVEO Pharmaceuticals, Inc.

Completed

Study of Tivozanib (AV-951) Plus FOLFOX6 in Subjects With Advanced Colorectal Cancer and Other Gastrointestinal Cancers

Colorectal Cancer | Gastrointestinal Cancer

Netherlands
Dana-Farber Cancer Institute
Bristol-Myers Squibb; Genentech, Inc.

Completed

Bevacizumab Plus Ipilimumab in Patients With Unresectable Stage III or IV Melanoma

Melanoma

United States
Azienda Ospedaliero, Universitaria Pisana

Completed

Folfoxiri Plus Bevacizumab Followed by Chemoradiotherapy Plus Bevacizumab in Patients With Resectable Rectal Cancer (TRUST)

Rectal Cancer

Italy
Wan-Guang Zhang
The Second Affiliated Hospital of Fujian Medical University; Geneplus-Beijing... and other collaborators

Recruiting

Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma (CCGLC-001)

Hepatocellular Carcinoma Non-resectable

China
Cancer Institute and Hospital, Chinese Academy...

Recruiting

The Efficacy and Safety of Modified XELOX(mXELOX) Plus Cetuximab vs FOLFOX Plus Cetuximab in RAS and BRAF WT mCRC Pts

Colo-rectal Cancer

China
Hospital Universitari de Bellvitge
Instituto de Salud Carlos III

Terminated

Resection vs no Resection of the Primary in Colorectal Cancer With Unresectable Metastases (CCRe-IV)

Colonic Cancer | Unresectable Metastasis Originating in Colonic Cancer

Spain
Fudan University

Recruiting

Cadonilimab in Combination With Bevacizumab and FOLFOX Regimen for the First-Line Treatment of Advanced Unresectable MSS-Type, RAS-Mutated Metastatic Colorectal Cancer

Metastatic Colorectal Cancer | Microsatellite Stable Colorectal Carcinoma | RAS Mutation | Cadonilimab

China
Tae Won Kim

Recruiting

DYNAmic Immune Microenvironment of HCC Treated With atezolIzumab Plus bevaCizumab (DYNAMIC)

Hepatocellular Carcinoma

Korea, Republic of
University of Pennsylvania
National Cancer Institute (NCI); American Cancer Society, Inc.

Completed

Self-Care for Head and Neck Cancer Survivors With Lymphedema and Fibrosis

Fibrosis | Head and Neck Cancer | Lymphedema

United States
Spanish Cooperative Group for the Treatment of...
Roche Pharma AG

Completed

Study of 5-Fluorouracil/Leucovorin/Oxaliplatin (FOLFOX) + Bevacizumab Versus 5-Fluorouracil/Leucovorin/Oxaliplatin/Irinotecan (FOLFOXIRI) + Bevacizumab as First Line Treatment of Patients With Metastatic Colorectal Cancer Not Previously Treated and With Three or More Circulating Tumoral Cells (VISNU-1)

Metastatic Colorectal Cancer

Spain
Holy Name Medical Center, Inc.
Women United in Philanthropy (WUIP)

Unknown

Intervention for Employed Women With Multiple Sclerosis

Multiple Sclerosis
Nanfang Hospital of Southern Medical University

Recruiting

Alternating Treatment With Fruquintinib and Bevacizumab Plus Capecitabine as Maintenance Therapy After First-Line Treatment in Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

China
Genentech, Inc.

Completed

A Study of PRO95780 Administered in Combination With the FOLFOX Regimen and Bevacizumab in Patients With Previously Untreated, Locally Advanced, Recurrent, and Metastatic Colorectal Cancer (APM4566g)

Metastatic Colorectal Cancer
Polaris Group

Terminated

Ph 1-2 Study ADI-PEG 20 Plus FOLFOX in Subjects With Advanced GI Malignancies Focusing on Hepatocellular Carcinoma

Hepatocellular Carcinoma | Gastric Cancer | Colorectal Cancer | Advanced Gastrointestinal (GI) Malignancies

United States, Taiwan, Korea, Republic of, United Kingdom, China, Italy
Fujian Cancer Hospital

Not yet recruiting

POF Versus FOLFOX Plus IP Paclitaxel in AGC

Gastric Cancer
Hoffmann-La Roche

Completed

A Study of Avastin (Bevacizumab) in Combination With XELOX or FOLFOX-4 in Patients With Metastatic Colorectal Cancer.

Colorectal Cancer

Canada, Australia, New Zealand
Memorial Sloan Kettering Cancer Center
Genentech, Inc.

Terminated

Neoadjuvant FOLFOX Plus Bevacizumab Chemotherapy in Patients With Locally Advanced Colon Cancer

Colon Cancer

United States
Koen Rovers
Hoffmann-La Roche; Comprehensive Cancer Centre The Netherlands; Dutch Cancer...

Recruiting

Perioperative Systemic Therapy for Isolated Resectable Colorectal Peritoneal Metastases (CAIRO6)

Colorectal Cancer | Peritoneal Neoplasms | Colorectal Neoplasm | Peritoneal Carcinomatosis | Colorectal Carcinoma | Peritoneal Cancer | Peritoneal Metastases | Colorectal Adenocarcinoma | Colorectal Neoplasms Malignant | Peritoneal Neoplasm Malignant Secondary Carcinomatosis | Peritoneal Neoplasm Malignant...

Netherlands, Belgium
Genentech, Inc.

Completed

A Study of Dulanermin Administered in Combination With the FOLFOX Regimen and Bevacizumab in Patients With Previously Untreated, Locally Advanced, Recurrent, or Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

United States
Fudan University

Recruiting

Conversion Therapy of RAS/BRAF Wild-Type Colorectal Cancer Patients With Initially Unresectable Liver Metastases

Colorectal Cancer | Liver Metastases

China
Peking University Cancer Hospital & Institute

Recruiting

Anti-PD-1/PD-L1 Combined With Anti-angiogenic Agents as First-line Treatment for Unresectable HCC

Unresectable Hepatocellular Carcinoma

China
Ain Shams University

Recruiting

the Effect of ABCC2 Genetic Polymorphism on Neurotoxicity in Gastrointestinal Cancer Patients Receiving Oxaliplatin

Gastrointestinal Cancer

Egypt
Yanhong Deng

Recruiting

Bevacizumab Plus mFOLFOXIRI as First-line Treatment for Patients With Unresectable Metastatic Colorectal Cancer (TRIBE-C)

Colorectal Cancer

China
Pfizer

Withdrawn

A Study Of Crizotinib Plus VEGF Inhibitor Combinations In Patients With Advanced Solid Tumors.

Carcinoma, Renal Cell | Glioblastoma | Carcinoma, Hepatocellular
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

Infusional FOLFOX Plus Camrelizumab and Apatinib vs HAIC-FOLFOX Plus Camrelizumab and Apatinib for Advanced HCC

Chemotherapy Effect | BCLC Stage C Hepatocellular Carcinoma

China
Yonsei University

Completed

Perioperative vs Postoperative Chemotherapy + Bevacizumab in Colorectal Cancer, Liver Mets

Colorectal Cancer | Liver Metastasis

Korea, Republic of
West China Hospital
First Affiliated Hospital of Chongqing Medical University

Recruiting

First-line mCapOX+Cetuximab vs. mFOLFOX6+Cetuximab for Metastatic Left-sided CRC With Wild-type RAS/BRAF Genes (CAPCET)

Colo-rectal Cancer | Capecitabine | Cetuximab

China
Henan Provincial People's Hospital

Not yet recruiting

Sintilimab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for ctDNAlevel- Relapse and Clinical-relapse Astrocytoma

Astrocytoma of Brain

China
Azienda Ospedaliero, Universitaria Pisana

Completed

Soluble Vascular Endothelial Growth Factor Receptor 2 as Predictor of Benefit From Bevacizumab Beyond Progression in Metastatic Colorectal Cancer (CIRCUS)

Metastatic Colorectal Cancer

Italy
Second Affiliated Hospital, School of Medicine,...

Recruiting

Fruquintinib Plus Capecitabine Versus Bevacizumab Plus Capecitabine as Maintenance Therapy Following First-line Treatment for Metastatic Colorectal Cancer

Colorectal Cancer

China
Asan Medical Center
Seoul National University Hospital; Hanyang University; Soon Chun Hyang University

Recruiting

Atezolizumab Plus Bevacizumab Alone or Combined With External Beam Radiotherapy for HCC With Macrovascular Invasion (ALERT-HCC)

Hepatocellular Carcinoma | Liver Cancer | Hepatocellular Carcinoma Non-resectable | Hepatocellular Cancer | Hepatocellular Carcinoma Stage IV

Korea, Republic of
University of Valencia
Asociación de Fibrosis Quística - Comunidad Valenciana

Not yet recruiting

e-Health Program to Prevent Exacerbations in the Cystic Fibrosis Population

Cystic Fibrosis

Spain
Sixth Affiliated Hospital, Sun Yat-sen University

Recruiting

mFOLFOX6+Bevacizumab+PD-1 Monoclonal Antibody in Local Advanced MSS CRC (BASKETⅡ)

Colorectal Cancer | Immunotherapy

China
Fudan University

Recruiting

VIC Regimen Versus Bevacizumab Plus Chemotherapy as First-Line Treatment for BRAF V600E-Mutated Advanced Colorectal Cancer

Colorectal Cancer

China
University of California, San Francisco
National Institute of Mental Health (NIMH)

Completed

Healthy Mood Internet Intervention Research Project

Major Depression

United States
Azienda Ospedaliero, Universitaria Pisana

Completed

First-line FOLFOXIRI Plus Bevacizumab in BRAF Mutant Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

Italy
Tongji Hospital
The Second Affiliated Hospital of Fujian Medical University; Geneplus-Beijing... and other collaborators

Recruiting

Combined TACE, TKI/Anti-VEGF and ICIs as Conversion Therapy for Advanced Hepatocellular Carcinoma (CCGLC-008)

Hepatocellular Carcinoma Non-resectable

China
Memorial Sloan Kettering Cancer Center

Active, not recruiting

Hepatic Arterial Infusion With Floxuridine and Dexamethasone Combination With Chemotherapy With/Without Bevacizumab for Hepatic Metastases From Colorectal Cancer

Rectal Cancer | Colon Cancer | Hepatic Metastases

United States
National Institute of Allergy and Infectious Diseases...

Completed

Evaluation of the Safety of and Immune Response to an HIV Vaccine in Healthy Adults

HIV Infections

Australia
Liaoning Tumor Hospital & Institute

Unknown

Bevacizumab Therapy Untreated Unresectable Liver Metastases From Colorectal Cancer

Colorectal Cancer | Liver Metastases

China
Taiwan Leader Biotech Corp.

Not yet recruiting

LEAC-102 for Advanced Colorectal Cancer

Advanced Colorectal Cancer
CHA University

Recruiting

Predictive Biomarkers in Patients With Advanced Hepatocellular Carcinoma Treated With Systemic Therapy (HCC)

Hepatocellular Carcinoma

Korea, Republic of
Boehringer Ingelheim

Completed

BIBF 1120 Versus Bevacizumab in Metastatic Colorectal Cancer

Colorectal Neoplasms

Belgium, France, Germany, Italy, Spain
Dizal Pharmaceuticals

Recruiting

DZD9008 In Combination With Bevacizumab in Locally Advanced or Metastatic NSCLC Patients With EGFR Mutation (WU-KONG29)

Non-small Cell Lung Cancer

China
Second Affiliated Hospital, School of Medicine,...

Recruiting

RC48-ADC Combined With Bevacizumab in HER2-positive Advanced Colorectal Cancer

Colorectal Cancer

China
Henan Provincial People's Hospital

Not yet recruiting

Sintilimab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for ctDNA-level-relapse and Clinical-relapse Glioblastoma

Glioblastoma

China
CHA University
Hoffmann-La Roche

Completed

Organ-specific Responses to Atezolizumab Plus Bevacizumab in Advanced HCC

Advanced Hepatocellular Carcinoma

Korea, Republic of

Search clinical trials for: Folfox plus Bevacizumab and reolysin

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Congo, DR of

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations